Cobimetinib

Cotellic®

Inhibition of MEK kinases 1 and 2 The MEK kinases are phosphorylated and activated by the mutated V600 BRAF kinases (MAP kinase signalling pathway).

09/2015

In combination with vemurafenib: non-resectable or metastatic melanoma with a BRAF V600 mutation.

Off-label use: for NRAS mutation as monotherapy, for uveal melanoma or melanoma from congenital nevi with NRAS mutation mosaic.

Differential blood count, biochemical panel, glucose, high-sensitivity troponin T, troponin I, NT-proBNP, S-100, blood pressure, ECG (QT time < 500 ms), Echocardiography (LVEF > 50%)

Dermatological assessment, ophthalmological examination (in case of ophthalmological symptoms)

Monthly: Differential blood count, biochemical panel, glucose, S-100, blood pressure
Monthly (until month 3), then quarterly: ECG (QT interval)
Quarterly: Dermatological assessment
After 4 weeks, then quarterly: Echocardiography, high-sensitivity troponin T, troponin I, NT-proBNP
 

Ophthalmological examination for changes in visual acuity

It is recommended to continue treatment until disease progression or unacceptable toxicity occurs.

60 mg orally, once daily for 21 days, followed by a 7-day break, in combination with vemurafenib.

Take care when taking strong CYP2C8 and CYP3A4 inhibitors (e.g. grapefruit, itraconazole) or inducers (e.g. St John's wort, rifampicin, phenytoin, carbamazepine) at the same time.

Refer to the relevant medical literature, guidelines, and study results.